Cedenio, Mary Anne .
HRN: 22-05-15 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/04/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
05/04/2023
05/14/2023
IV
600mg
Q6h
Infected Breast Mass
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes